Publication: Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen
Issued Date
2010-02-15
Resource Type
ISSN
10584838
DOI
Other identifier(s)
2-s2.0-75749110161
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Infectious Diseases. Vol.50, No.4 (2010), 597-604
Suggested Citation
Wittaya Wangsomboonsiri, Surakameth Mahasirimongkol, Soranun Chantarangsu, Sasisopin Kiertiburanakul, Angkana Charoenyingwattana, Surat Komindr, Chupong Thongnak, Taisei Mushiroda, Yusuke Nakamura, Wasun Chantratita, Somnuek Sungkanuparph Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clinical Infectious Diseases. Vol.50, No.4 (2010), 597-604. doi:10.1086/650003 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/29768
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Association between HLA-B*4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen
Abstract
Background. Stavudine-containing antiretroviral regimens are widely used in developing countries. Stavudineassociated lipodystrophy commonly occurs, without a clear predictable pattern owing to the unknown interaction between stavudine and the host, among patients who received this regimen. The aim of this study was to determine the clinical risk factors and human leukocyte antigen (HLA) alleles associated with stavudine-associated lipodystrophy. Methods. A case-control, cross-sectional study was conducted for HIV-infected patients receiving stavudinecontaining antiretroviral regimens. Clinical assessments for lipodystrophy by physical examination, anthropometry, and dual-energy X-ray absorptiometry were obtained. On the basis of their clinical assessment, the patients were classified into 2 groups: the case group (moderated to severe lipodystrophy) and the control group (absent to mild lipodystrophy). The clinical characteristics and allelic distribution of HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-DPB1 were compared between the case group and the control group, to determine the possible association with stavudine-associated lipodystrophy. Results. There were 103 patients; 55 patients were in the case group, and 48 patients were in the control group. By use of forward stepwise logistic regression, the presence of HLA-B*4001 (odds ratio [OR], 14.05; 95% confidence interval [CI], 2.57-76.59; P =.002) and a longer duration of stavudine treatment (OR, 1.02; 95% CI, 1.00-1.04; P =.02) were significantly associated with stavudine-associated lipodystrophy, whereas a higher body mass index during treatment (OR, 0.73; 95% CI, 0.61-0.86; P<.001) was associated with a lower risk for lipodystrophy. HLA-B*4001 has a high specificity (95.8%) and a positive predictive value (88.9%) for lipodystrophy. Conclusions. HLA-B*4001 is a strong genetic risk factor for stavudine-associated lipodystrophy in HIV-infected patients in Thailand. HLA-B*4001 may be used as a genetic marker to predict which patients will develop stavudineassociated lipodystrophy, to avoid or shorten the duration of stavudine use. This finding needs to be confirmed in further replication studies. © 2010 by the Infectious Diseases Society of America. All rights reserved.